順豐控股(06936.HK)完成發行29.5億零息有擔保可換股債券
順豐控股(06936.HK)公布,於7月10日(今日)完成發行29.5億零息有擔保可換股債券。配售所得款項淨額預計約為29.3億元。債券於聯交所上市及買賣的批准預計將於7月11日生效。
債券可依照條款及條件轉換成轉換股份。假設債券全部按每股H股48.47元的初始轉換價進行轉換,並且不再發行其他股份,債券將轉換成約6,085.9萬股轉換股份,約佔公司現有已發行H股數目的25.4%及現有已發行股本的1.2%;以及約佔公司於債券獲悉數轉換後經發行轉換股份擴大後已發行H股數目的20.2%及已發行股本的1.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.